Non-small cell lung cancer
Conditions
Interventions
With COVID-19 history group:None
Without COVID-19 history group:None
Sponsors
Shanghai Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Age range from 18 to 90 years old, gender not specified. 2. Preoperative assessment confirms resectable lesions. 3. Underwent robot-assisted, thoracoscopic, or traditional open-chest lung surgery, with pathology confirming NSCLC. 4. ECOG performance status score of 0-1. 5. Good organ function. 6. Willing and able to comply with the study protocol's visits, treatment schedules, laboratory tests, and other research procedures.
Exclusion criteria
Exclusion criteria: Patients meeting any of the following exclusion criteria cannot be enrolled in this study: 1. Inability to confirm prior COVID-19 infection. 2. Surgery performed less than 1 month after COVID-19 seroconversion. 3. Newly diagnosed COVID-19 infection during the perioperative period. 4. Non-curative resection of lung cancer. 5. History of (non-infectious) pneumonia/interstitial lung disease requiring steroid treatment, or currently requiring steroid treatment for pneumonia/interstitial lung disease. 6. Known active tuberculosis history. 7. Known active infection requiring systemic treatment. 8. Any known or suspected autoimmune disease or immune deficiency, except patients with a history of hypothyroidism not requiring steroid treatment, or those receiving physiological doses of steroid replacement therapy; stable type I diabetes with controlled blood sugar. 9. Uncontrolled active hepatitis B (defined as positive screening for hepatitis B surface antigen [HBsAg] with HBV-DNA levels above the upper limit of normal for the laboratory at the study center; patients with HBV-DNA levels <500 IU/mL and receiving at least 14 days of local standard antiviral therapy and willing to continue antiviral therapy during the study period may be enrolled); active hepatitis C (defined as positive screening for hepatitis C surface antibody [HCsAb] with positive HCV-RNA). 10. Known human immunodeficiency virus (HIV) infection (known HIV antibody positive). 11. Vaccination with live vaccines within 30 days prior to the first dose. This includes but is not limited to: mumps, rubella, measles, varicella/zoster (chickenpox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG) and typhoid vaccines (killed virus vaccines are allowed). 12. Known severe or uncontrolled underlying diseases, including but not limited to hemodynamically unstable cardiovascular events within the past 6 months, symptomatic cerebrovascular events, and Child-Pugh class A or above cirrhosis. 13. Presence of any medical history, treatment, or laboratory abnormalities judged by the investigator to potentially confound study results or not in the best interest of the patient's participation in the study, based on current evidence.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative complications; | — |
Secondary
| Measure | Time frame |
|---|---|
| Operation duration;Length of postoperative hospitalization; | — |
Countries
China
Contacts
Public ContactLuo Qingquan
Shanghai Chest Hospital
Outcome results
None listed